

Award Number: W81XWH-09-1-0091

TITLE: A Randomized Placebo-Controlled Trial of D-Cycloserine for the Enhancement of Social Skills Training in Pervasive Development Disorders

PRINCIPAL INVESTIGATOR: Dr. Marjorie McCaskey

CONTRACTING ORGANIZATION: Indiana University Health
Indianapolis, IN 46202

REPORT DATE: March 2015

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE**Form Approved**
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Service, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188) Washington, DC 20503.

PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**1. REPORT DATE (DD-MM-YYYY)**

March 2015

2. REPORT TYPE

Annual

3. DATES COVERED (From - To)

1 Mar 2014 - 28 Feb 2015

4. TITLE AND SUBTITLE

A Randomized Placebo-Controlled Trial of D-Cycloserine for the
Enhancement of Social Skills Training in Pervasive
Development Disorders

5a. CONTRACT NUMBER**5b. GRANT NUMBER** W81XWH -09-1-0091**5c. PROGRAM ELEMENT NUMBER****6. AUTHOR(S)**

Noha Minshawi-Patterson, PhD
nminshaw@iupui.edu

Dr. Marjorie McCaskey
mmccaske@iuhealth.org,

5d. PROJECT NUMBER**5e. TASK NUMBER****5f. WORK UNIT NUMBER****7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)**

Indiana University Health Partners Inc.
1701 N. Senate Blvd.
Indianapolis, IN 46202-5012

**8. PERFORMING ORGANIZATION
REPORT NUMBER****9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)**

U.S. Army Medical Research and Material Command
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR'S ACRONYM(S)**11. SPONSORING/MONITORING
AGENCY REPORT NUMBER****12. DISTRIBUTION AVAILABILITY STATEMENT**

Approved for public release; distribution unlimited.

13. SUPPLEMENTARY NOTES**14. ABSTRACT -**

attached

15. SUBJECT TERMS**16. SECURITY CLASSIFICATION OF:**

a. REPORT

b. ABSTRACT

c. THIS PAGE

**17. LIMITATION OF
ABSTRACT****18. NUMBER
OF PAGES**

28

19a. NAME OF RESPONSIBLE PERSON
USAMRMC**19b. TELEPHONE NUMBER (Include area code)**

Table of Contents

	Page
Abstract.....	4
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusion.....	5
References.....	6
Appendices.....	6

ABSTRACT

The main objective of this application is to determine whether D-cycloserine (DCS) can enhance the efficacy of social skills training (SST) in the treatment of children and young adolescents with autism spectrum disorders (ASDs). We will evaluate the efficacy, tolerability, and last effects of DCS given one hour prior to each of 10 weekly SST sessions for the treatment of social impairment in 68 children and young adolescents (ages 5-11 years) with ASDs during a randomized placebo-controlled trial. The safety and tolerability of DCS and durability of treatment response will also be examined.

In 2011, IRB approval received to allow for enrollment of youth with 1) stable seizure disorders and 2) up to two concomitant psychotropic non-glutamatergic drugs. Approval also received for the addition of the Autism Diagnostic Observation Schedule (ADOS) to better characterize ASD pathology.

In 2012, the study was expanded to include a second site, led by former Indiana University site PI Craig Erickson, at Cincinnati Children's Hospital Medical Center. This expansion increased the overall study N to 68 youth with ASD and 34 neurotypical peers (originally 52 youth with ASD and 26 neurotypical peers at Indiana University only). Dr. Noha Minshawi was also named lead PI at the Indiana University Site at that time. In addition, IRB approval received to 1) complete TRIAD Social Skills Assessment (TSSA) and Eye Tracking with typically developing peers to provide a normative sample, and 2) record Play Coding behaviors of the typically developing peers from the Social Skills Training sessions.

INTRODUCTION

The long-range goal of this research is to identify better treatments for the core social and communication impairment of autism spectrum disorders (ASDs). The main objective of this application is to determine whether D-cycloserine (DCS) can enhance the efficacy of social skills training (SST) in the treatment of children and young adolescents with ASDs. The central hypothesis is that DCS will enhance the learning of social skills over the course of 10 weeks of SST. To test this hypothesis, we will evaluate the efficacy of DCS given one hour prior to each of 10 weekly SST sessions for the treatment of social impairment in 68 children and young adolescents (ages 5-11 years) with ASDs during a randomized placebo-controlled trial. The safety and tolerability of DCS and durability of treatment response will also be examined.

BODY

- August 5, 2009 - Final IRB approval was obtained.
- December 25, 2009 – IRB approved an amendment containing initial revisions requested by the Department of Defense Human Research Protections Office (HRPO).
- February 4, 2010 - IRB approved an amendment containing final revisions requested by the HRPO.
- March 1, 2010 – Enrollment began at IU.
- March 1 – December 31, 2010 – Two SST groups conducted with a total of 8 children with ASD and 4 typically developing peers at IU.
- January 1 – December 31, 2011 – Four SST groups conducted with a total of 16 children with ASD and 8 typically developing peers at IU.

- January 1 – December 31, 2012 - Four SST groups conducted with a total of 16 children with ASD and 8 typically developing peers at IU.
- January 1 – December 31, 2013 – Three SST groups conducted with a total of 12 children with ASD and 6 typically developing peers at IU.

KEY RESEARCH ACCOMPLISHMENTS

- January 1 - December 31, 2014 - All data collection completed. Data entered into databases, cleaned, and initial data analyses conducted.
- Enrollment is completed. A total of 13 SST groups were conducted across both sites. At the Indiana University site, 52 children with ASD and 26 children with neurotypical development. A total of 4 SST groups were completed at the Cincinnati Children's Hospital Medical Center site, with 16 children with ASD and 8 children with neurotypical development.
- All follow up visits and data collection were completed in January 2014 at IU.
- Biostatisticians were consulted to develop data analysis plan for the primary outcome data and these analyses were conducted. The primary outcome manuscript was written and submitted to the Journal of the Academy of Child and Adolescent Psychiatry in December 2014.

REPORTABLE OUTCOMES

Primary outcome analysis has been conducted. Please see attached manuscript for full reportable outcomes, tables and figures.

CONCLUSION

The results of this trial demonstrated no drug-related short-term improvement on the primary outcome measure, or any of the secondary outcome measures. However, an overall significant improvement in primary outcome measure, Social Responsiveness Scale total raw score, was observed from baseline to end of treatment for the entire group of children with PDD. This suggests a need to further study the efficacy of the social skills training protocol. There are several possible explanations for the lack of pharmacological treatment effect in this study. When examining the characterization of the sample, the majority of subjects enrolled in this study were diagnosed with PDD-NOS and Asperger's Disorder. These diagnoses indicate an overall milder symptom presentation, which may have potentially introduced a ceiling effect whereby there was less room for improvement with the treatment. Another potential reason for lack of drug effect in the current study is that social interactions, and therefore social deficits, are difficult behaviors to objectively quantify due to the ways in which social behavior changes in different settings and circumstances and over time. Additional analysis of the a more direct, objective measurement of social behavior and social interest, eye tracking, is planned to assess potential changes in social interaction which occurs at a level not readily observable by caregivers and clinicians.

REFERENCES:

Minshawi, N. F., Wink, L., Shaffer, R., Plawecki, M., Posey, D., McDougle, C.J., Swiezy, N., & Erickson, C. (under review). A randomized, placebo-controlled trial of D-Cycloserine for the enhancement of social skills training in Autism Spectrum Disorders. *Journal of Child and Adolescent Psychiatry*.

APPENDICES:

Manuscript of primary outcomes (submitted to the Journal of the Academy of Child and Adolescent Psychiatry in December 2014) is attached. We are still awaiting feedback from the journal editors on the status of this paper.

SUPPORTING DATA:

Please see attached manuscript for full data analysis of the primary outcomes.

RUNNING HEAD: D-Cycloserine and social skills training

**A Randomized, Placebo-Controlled Trial of D-Cycloserine for the Enhancement of
Social Skills Training in Autism Spectrum Disorders**

Noha F. Minshawi, Ph.D.¹, Logan K. Wink, M.D.², Rebecca Shaffer Psy.D.², Martin H. Plawecki M.D., Ph.D.¹,
David J. Posey, M.D.³, Hai Liu, Ph.D.⁴, Sarah Hurwitz, Ph.D.⁵, Christopher J. McDougle, M.D.⁶, Naomi B.
Swiezy, Ph.D.¹, and Craig A. Erickson, M.D.²

¹Christian Sarkine Autism Treatment Center
Riley Hospital for Children at Indiana University Health
Indiana University School of Medicine Department of Psychiatry
Indianapolis, Indiana

²Cincinnati Children's Hospital Medical Center
University of Cincinnati College of Medicine
Cincinnati, Ohio

³David J. Posey, M.D., LLC
Indianapolis, Indiana

⁴Indiana University School of Medicine
Department of Biostatistics
Indianapolis, Indiana

⁵Indiana University
School of Education
Bloomington, Indiana

⁶Lurie Center for Autism
Departments of Psychiatry and Pediatrics
Massachusetts General Hospital and MassGeneral Hospital *for* Children
Harvard Medical School
Boston, Massachusetts

Keywords: D-cycloserine, Autism Spectrum Disorders, social skills training, social deficits

Acknowledgements: Funding for this study was provided by the United States Department of Defense. Statistical support was provided by Hai Liu, Ph.D., Indiana University School of Medicine Department of Biostatistics. We would like to acknowledge the contributions of Stacie Pozdol, M.A., Carrie McGinnis, B.S., CCRP, and Lyndsi Moser, B. S., CCRP at Indiana University and Katherin Friedmann, RN, Lauren Mathieu-Frasier, MA, and Tori Schaefer, PhD at Cincinnati Children's Hospital Medical Center.

Corresponding Author:

Craig A. Erickson, M.D.
Cincinnati Children's Hospital Medical Center
3333 Burnet Avenue MLC 4002
Cincinnati, OH 45229
Email: craig.erickson@cchmc.org
Office Direct: 513-636-6265

Words in Abstract: 234, Words in Text: 6059, Number of Tables: 4, Number of Figures: 1,
Supplementary Materials: 0

Abstract

Objective: Researchers have demonstrated that D-cylcoserine (DCS) can enhance the effects of behavioral interventions in adults with anxiety and enhance prosocial behavior in animal models of Autism Spectrum Disorders (ASD). This study extended upon this background by combining DCS with behavioral social skills therapy in youth with ASD to assess its impact on the core social deficits of ASD. We hypothesized that DCS used in combination with social skills training would enhance the acquisition of social skills in children with ASD.

Method: A 10-week, double-blind, placebo-controlled trial of DCS (50 mg) given 30 minutes prior to weekly group social skills training was conducted at two sites. Children with ASD were randomized to receive 10 weeks (10 doses) of DCS or placebo in a 1:1 ratio.

Results: No statistically significant difference attributable to drug treatment was observed in the change scores for the primary outcome measure, the Social Responsiveness Scale (SRS), total score ($p=0.45$) or on secondary outcome measures.

Conclusions: The results of this trial demonstrated no drug-related short-term improvement on the primary outcome measure, or any of the secondary outcome measures. However, an overall significant improvement in SRS total raw score was observed from baseline to end of treatment for the entire group of children with ASD. This suggests a need to further study the efficacy of the social skills training protocol. Limitations to the current study and areas for future research are discussed.

Introduction

Autism Spectrum Disorders (ASD), including Autistic Disorder, Asperger's Disorder and Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS), have received increasing attention from researchers, clinicians, and the public since autism was first described by Leo Kanner in 1943¹. The diagnosis of ASD is characterized by core social and communication deficits, as well as restricted, repetitive behaviors. In recent years, the rates of ASD have escalated, with the most recent Centers for Disease Control and Prevention data estimating prevalence at 1 in 68 children in the United States². While some successful pharmacological and behavioral interventions have been identified for the treatment of hyperactivity/inattention and irritability associated with ASD, little progress has been made in the effective treatment of primary social and communication deficits. The limited success of clinical trials targeting core social impairment in ASD is likely in part due to the heterogeneity of ASD, difficulty quantitatively tracking treatment response, and high placebo response rates. Regardless, the lack of viable treatments is particularly concerning given that pervasive social impairment in ASD can limit lifelong functioning and independence³.

Research in psychiatric disorders has led to some advances in ASD research. Specifically, a parallel is frequently drawn between schizophrenia and ASD due to similarity between the negative symptoms of schizophrenia and social withdrawal seen in ASD, as well as the implication of glutamate dysregulation in both disorders⁴. Consequently, several targeted treatment trials in both ASD and schizophrenia have focused on modulating glutamate neurotransmission^{5,6}. D-cycloserine (DCS), a partial agonist of the *N*-methyl-D-aspartate (NMDA) glutamate receptor and a Food and Drug Administration-approved treatment for tuberculosis, has been researched for treatment of negative symptoms of schizophrenia with mixed results⁶⁻¹⁰. In ASD, a single-blind pilot study of DCS in children and adults (mean age of 10 years) found that DCS was associated with a clinically significant reduction in social withdrawal and increase in social responsiveness compared to a placebo control¹¹. However, a double-blind, placebo-controlled trial of daily dosing of DCS in 88 children with ASD found no significant difference in measures of social withdrawal or global severity ratings during 8 weeks of daily treatment¹².

Glutamatergic neurotransmission has also been of interest in the treatment of anxiety disorders^{13,14}. A growing body of preclinical and clinical research has demonstrated the ability of DCS to enhance learning in the treatment of anxiety symptoms¹⁵. The mechanism believed to be responsible for this effect is the enhancement of learned extinction of fear responses via combination Cognitive Behavior Therapy (CBT) and DCS treatment^{15,16}.

Results have shown that DCS plays an augmentative role in the learning that takes place during CBT and therefore leads to greater success than when CBT is used alone.

The promising results from anxiety studies have subsequently led to the investigation of combined DCS plus targeting social learning in animal models of ASD. Modi and Young¹⁷ demonstrated that DCS combined with social learning paradigms in mice increased prosocial bonding and partner selection. To date, no studies of combined DCS plus non-drug therapy have been published in ASD. Based on this background, we investigated DCS treatment in combination with behavior therapy in youth with ASD. We hypothesized that DCS used in combination with Applied Behavior Analysis-based social skills training (ABA), the most empirically supported behavioral intervention for ASD¹⁸, would enhance the acquisition of social skills in children with ASD. We additionally hypothesized that children treated with DCS would show greater improvement in social functioning from social skills training than those taking placebo.

Method

Study Design

A 10-week, double-blind, placebo-controlled trial of low dose (50 mg) DCS given 30 minutes prior to weekly group social skills training was conducted at two sites, Indiana University School of Medicine and Cincinnati Children's Hospital Medical Center. Children with ASD were randomized to receive 10 weeks (10 doses) of DCS or placebo in a 1:1 ratio. All children received 10 weeks of manualized social skills training. Children were further divided into two age groups, 5-7 years and 8-11 years, for the purposes of keeping social skills groups more homogeneous. Each social skills group included up to four children with ASD and two typically-developing peer models (TPs) in the same age group. The TPs participated in all group activities but did not take DCS or placebo. Adverse Events (AEs) and interval history were collected prior to dosing and outcome measures were administered at baseline, week 6, and week 11. This trial was approved by the Institutional Review Board at each site.

Participants

Sixty-seven children with ASD ages 5-11 years participated in the study along with 34 typically-developing, same-aged children who served as TPs. One subject with ASD was excluded from analyses due to early dropout prior to taking the study drug. Participants were recruited from academic autism treatment centers, local schools, and community organizations. Written informed consent was obtained from legal guardians and assent was obtained when participants were able. Diagnosis of ASD was made through administration of the *Autism Diagnostic*

Observation Schedule^{19,20}, *Autism Diagnostic Interview-Revised*²¹, and clinical interview using the *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision* (DSM-IV-TR)²² criteria for Autistic Disorder, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).

Subjects with ASD were required to have an Intellectual Quotient greater than 70 on the *Stanford-Binet 5th Edition*²³ (SB-V) and a communication standard score greater than 70 on the *Vineland Adaptive Behavior Scale 2nd Edition* (VABS-II)²⁴ survey edition. These criteria were included to ensure that participants did not have cognitive or language deficits that could interfere with their ability to participate in group social skills training. Additional inclusion criteria included a *Triad Social Skills Assessment* (TSSA)²⁵ score of 70% or less on both parent questionnaire and child assessment, significant social impairment as measured by a T-score of 60 or greater on the *Social Responsiveness Scale* (SRS)²⁶ and Clinical Global Impression Severity (CGI-S) scale score of at least four ("Moderately Ill"). The CGI-S is a clinician-rated global assessment of symptom severity. The CGI-S item is rated on a scale from 1 to 7 (1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill patients). Rater training was conducted with gold standard vignettes and inter-rater reliability of 80% or greater was established.

Study participants were required to remain on stable psychotropic medication dosing targeting symptoms associated with ASD (e.g., insomnia, inattention, hyperactivity, anxiety, irritability) for a minimum of two weeks (with the exception of four weeks for fluoxetine) prior to randomization. Potential participants were excluded if they were taking more than two psychotropic medications or if they were currently taking a glutamatergic modulator (e.g., riluzole, memantine, acamprosate, topiramate, amantadine). In addition, concomitant psychosocial treatments could not include group social skills training outside of the study and all therapies were required to have been stable for at least 90 days prior to randomization.

The TPs were screened with the *Child Symptom Inventory-4*²⁷ to ensure that they did not have a history of psychiatric symptoms that were currently affecting social skills (e.g., attention-deficit/hyperactivity disorder, oppositional defiant disorder, schizophrenia, ASD, social anxiety disorder, and major depression). The child's appropriateness for inclusion in the social skills groups (e.g., absence of social, behavioral, or language problems) was also assessed by a trained clinician. Parents of TPs provided informed consent and TPs provided assent.

Social Skills Training

Social skills groups were conducted following a manualized curriculum adapted for use in the present study. The curriculum utilized ABA-based methodologies, including shaping, incidental teaching, positive reinforcement, and visual schedules, as well as social stories and weekly parent-mediated homework assignments. The TPs assisted in modeling and reinforcing appropriate behavior during each group session. Each week focused on a specific social skill (e.g., greeting others, emotional understanding, play skills, saying goodbye, conversations), and this skill was taught through a number of different didactic and experiential activities (e.g., social stories, discussions, crafts, worksheets). Minor modifications were made to curriculum based on the age group (5-7 or 8-11 year olds) to enhance understanding and developmental appropriateness. Social groups were facilitated by masters or doctoral-level clinicians with expertise in ASD and ABA.

Prior to the start of social skills training, TPs were educated in a separate session. An introduction to behaviors associated with ASD was presented, along with an overview of the social skills curriculum and weekly schedule. In addition, TPs engaged in role play with the clinicians to practice appropriate skills and corrective feedback was provided. A social story on ASD was also provided for the TPs to review at home with their parents prior to the first social skills group.

Primary Outcome

The primary outcome measure of social relatedness in participants with ASD was the parent-rated SRS total raw score. The SRS is a standardized, 65-item measure of the core symptoms of ASD where each item is scored on a 4-point scale, which has been used extensively in ASD research²⁸⁻³¹. The SRS was administered at screen, baseline, week 6 (after 5 weeks of SST), and at week 11 (after 10 weeks of social skills training).

Secondary Outcomes

Several secondary outcome measures were included to capture different aspects of ASD that could be affected by the proposed treatment. When available, SRS data was collected from teachers of the subjects with ASD at baseline, week 6, and week 11. Additionally, all participants were evaluated using the VABS-II, Aberrant Behavior Checklist (ABC)³², Clinical Global Impression Improvement Scale (CGI-I), and the TSSA, at baseline and week 11.

The adaptive functioning of subjects was evaluated at baseline and week 11 using the VABS-II. The VABS-II assesses adaptive functioning in four domains: Communication, Daily Living Skills, Socialization, and Motor Skills. Administered via semi-structured interview with parents or caregiver, the VABS-II provides a measure of overall functioning of children and adults. The VABS-II is a standardized, norm-referenced assessment that is used extensively in individuals with ASD^{33,34}.

The ABC was collected at baseline, week 6 and week 11 to assess the impact of the treatment on symptoms relevant to ASD. The ABC is a 58-item parent questionnaire with five subscales derived by factor analysis: Irritability, Social Withdrawal, Stereotypy, Hyperactivity, and Inappropriate Speech. The ABC has been extensively used in psychopharmacological studies of ASD³⁵. When available, teachers of the subjects with ASD were also asked to complete the ABC at the same time points.

The CGI-I was utilized as a clinician-rated dichotomous outcome measure to assess response to treatment. A trained clinician blind to treatment assignment rated the CGI-S at baseline and the CGI-I at each visit following randomization. Factors included in rating the CGI-I included parent report, parent-rated measures, teacher-rated measures, and clinician-rated measures. The CGI-I provides a qualitative measure of treatment response through a rating from 1 to 7 (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse). Rater training was conducted with gold standard vignettes and inter-rater reliability of 80% or greater was established. At the end of treatment subjects with a CGI-I of “1” or “2” were categorized as responding to the treatment and subjects with CGI-I scores of “3” or higher were categorized as nonresponders.

To assess the impact of the treatment on social skills and social knowledge, the TSSA was administered to the subjects and their parents at baseline and week 11. The TSSA is a criterion-based assessment that addresses three components of social knowledge and skills: cognitive (ability to problem-solve interpersonal conflicts), behavioral (ability to initiate and maintain interactions and respond appropriately to others), and affective (ability to understand emotions). The TSSA has been used as a supplemental descriptive measure of social skills³⁶, as well as in treatment planning³⁷.

Finally, monitoring for AEs was completed at each visit for subjects with ASD. The site physician kept a log of AEs that included the date of onset, date of resolution, severity, and relationship to study intervention (e.g., definite, probable, possible, remote, or none).

Statistical Analysis

Study participants' demographic and clinical characteristics were summarized and compared between the DCS and placebo groups at baseline using two-sample *t*-tests for continuous variables and Fisher's exact tests for categorical variables. The change scores of the primary outcome variables (SRS total score and subscales) from baseline to 11-week follow-up were also compared between the two treatment groups using *t*-tests. Similar analyses were conducted for the secondary outcomes including VABS-II total score and subscales, ABC subscales and TSSA parent report. In addition, a linear mixed effects modeling was used to further test the treatment effect over time using longitudinal SRS total scores measured at baseline, 6-week and 11-week visits. Responder analysis (responders were defined as "much improved" or "very much improved" for CGI-I at 11-week follow-up) was conducted using Chi-square test. AEs during the treatment period were also analyzed. All analyses were performed using SAS version 9.2.

Results

Thirty-four participants were randomized to the DCS treatment group and 33 were randomized to the placebo group. One subject who was randomized to the placebo group dropped out of the study before taking any medication and subsequently was excluded from analysis. Comparisons between the two groups showed no statistically significant difference in age, sex, SB-V scores, the VABS-II Expressive Language subscale, the CGI-S, concomitant medications, or concomitant therapy treatments at baseline (Table 1). Therefore, no potential confounders were adjusted for as covariates in all subsequent analyses. Furthermore, no significant differences were noted between the two sites (Cincinnati and Indiana University) on demographic variables (Table 2).

Insert Table 1 here

Insert Table 2 here

No statistically significant difference attributable to drug treatment was observed in the change scores for the SRS total score ($p=0.45$). Additionally, no significant differences were identified between groups in the change scores for the secondary outcome measures were identified (Table 3). In addition, teacher-rated ABC data was returned for 23.5% of the DCS group and 30.3% of the placebo group with no significant difference noted for any of the ABC subscales (Irritability $p=0.623$, Social Withdrawal $p=0.845$, Stereotypy $p=0.434$, Hyperactivity $p=0.833$,

and Inappropriate Speech $p=0.959$) between groups. Teacher-rated SRS data was available for 26.4% of the DCS group and 27.2% of the placebo group, and again no significant difference was found between groups ($p=0.59$).

Insert Table 3 here

In addition to the primary endpoint of the study at Week 11, the SRS total score was also measured at Week 6. A linear mixed effects model was fitted to further test the treatment effect over time using data at all three visits. Again, there was no significant difference between the two treatment groups ($p = 0.502$). The repeated measures of SRS total scores are depicted in Figure 1.

Insert Figure 1 here

A responder analysis was conducted based on CGI-I scores at 11-week follow-up. For the responder analysis, 33.3% of participants in the DCS group were classified as responders to treatment based on the CGI-I, as compared to 32.3% in the placebo group, which showed no significant difference in rate of response between groups ($p = 0.927$). Based on the observed trend of improvement in both treatment groups, subjects were combined to assess whether SRS total score changed significantly from baseline to week 11. A paired t-test for all 67 subjects with ASD showed a mean change score of -15.14 with 95% confidence interval (-19.90, -10.38), $p < 0.0001$.

Adverse Events

Table 4 shows the number of subjects who reported an adverse event, as well as all categories of AEs where at least 10% of either group (DCS or placebo) reported experiencing that AE. Fisher's Exact tests were utilized to derive p values. No category of adverse event showed a statistically significant difference between groups. The DCS group experienced more emesis than the placebo group (17.6% vs 6.1%, $p=0.26$). Overall, more patients in the DCS group reported at least one adverse event compared to the placebo group (94.2% vs. 84.8%) although this difference was not significant ($p=0.21$). The placebo group had a higher number of total adverse events (149 vs. 138) ($p=0.87$). Finally, only one serious adverse event (one instance of making a suicidal comment at school when angry) was reported in the placebo group.

Insert Table 4 here

Discussion

The core social deficits seen in ASD are severely impairing and few interventions have been identified to successfully and consistently treat these impairments. Several promising studies have shown DCS to enhance behavioral therapy outcomes in individuals with anxiety disorders, as well as demonstrating potential benefits of DCS treatment in ASD. The present study extended these lines of study by evaluating DCS mediated enhancement of the learning of social skills in children with ASD. The results of this double-blind placebo-controlled short-term trial demonstrate no drug-related improvement on the primary outcome measure, or any of the secondary outcome measures. However, an overall significant improvement in SRS total raw score was observed from baseline to end of treatment for the entire group of children with ASD.

There are several possible explanations for the lack of pharmacological treatment effect in this study. When examining the characterization of the sample, the majority of subjects enrolled in this study were diagnosed with PDD-NOS and Asperger's Disorder. These diagnoses indicates an overall milder symptom presentation, though a minimum SRS score indicated significant social impairment was required for study entry for all subjects. Children diagnosed with PDD-NOS and Asperger's Disorder may demonstrate less severe social deficits and other symptoms compared to youth with Autistic Disorder. This may have potentially introduced a ceiling effect whereby there was less room for improvement with the treatment. However, this complication is not unique to this study. The heterogeneity of ASD makes this a particularly challenging population to study and all the more difficult to find effective pharmacological and behavioral interventions. It is also important to note that since study enrollment ended, the *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition*³⁸ (DSM-5) has been published with revisions resulting in a new category of diagnosis called Autism Spectrum Disorder, along with the restructuring of diagnostic criteria. However, we do not believe these diagnostic changes would have influenced the results of the current study.

Another potential reason for lack of drug effect in the current study is that social interactions, and therefore social deficits, are difficult behaviors to objectively quantify due to the ways in which social behavior changes in different settings and circumstances and over time. This study utilized the parent-rated SRS total raw score to evaluate social deficits in ASD. The SRS provides a global perspective on social deficits in ASD. However, the

learning occurring during social skills training may not produce effects sufficiently robust to alter these broad, subjective social skills ratings. In the future, a more direct, objective measurement of social behavior and social interest, such as eye tracking, may be required to capture change in social interaction which occurs at a level not readily observable by caregivers and clinicians.

Several additional factors should be considered in evaluating the findings of the current study. Based on the effective dose of DCS used in studies of DCS plus therapy for treatment of phobias and social anxiety, all subjects in this trial received 50 mg of DCS regardless of weight^{39,40}. It is possible that higher doses (potentially weight-based) may have resulted in greater improvement for the DCS group. However, the phobia study by Ressler et al. (2004) demonstrated no difference between 50 mg and 500 mg doses of DCS so it is unclear what impact dosage adjustment may have provided³⁹. Longer duration and more frequent treatment may also need to be considered. Ten weekly doses of DCS and social skills training may not be sufficient to make robust changes in symptoms of social impairment and extended length of treatment and/or daily dosing may be necessary. In addition, the psychotherapy studies referenced in the development of this protocol dealt with operant conditioning via learned extinction. The current study, utilized some operant conditioning techniques (such as reinforcement), but also used other learning mechanisms in the training of social skills (such as social learning through modeling and role playing). It is possible that DCS has its greatest influence over learned extinction and our negative results may reveal the limitation of our employed learning mechanism.

Finally, a limitation of this study is the lack of a control for the social skills training group. All children enrolled in the study received 10 weeks of social skills training and statistically significant improvements were seen across the outcome measures when drug and placebo groups were combined. These results may point to the efficacy of this social skills training protocol at improving social outcomes for children with ASD. However, this potential mechanism cannot be confirmed without controlling for other factors that potentially influenced the results, such as maturation, time with trained clinicians, attention, and access to peers. A placebo or waitlist control group should be employed in future studies to evaluate the efficacy of our social skills curriculum.

The present study provides proof of concept that a large sample study combining medication and social skills training in ASD is feasible. Few studies have been conducted in ASD combining pharmacological and behavioral interventions, despite the common blending of these interventions in clinical settings. Future research on the role of targeted drug treatments in augmenting behavioral interventions in ASD is warranted. Despite the

negative result of this short-term drug augmentation analysis, we believe further work focused on durability of treatment response is needed to assess long-term outcome following initial combination treatment in this and other similar projects. Overall, utilizing targeted drug treatment to facilitate learning and acquisition of skills during therapy in ASD warrants additional investigation. Lessons learned in our study of DCS as a potential augmentation strategy to social skills training lays the groundwork for such work.

References

1. Kanner L. Autistic disturbances of affective contact. *Nervous Child*. 1943;2:217-250.
2. CDC. *Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2010*. 2010.
3. Magiati I, Tay XW, Howlin P. Cognitive, language, social and behavioural outcomes in adults with autism spectrum disorders: A systematic review of longitudinal follow-up studies in adulthood. *Clinical Psychology Review*. 2014;34(1):73-86.
4. McDougle CJ, Erickson CA, Stigler KA, Posey DJ. Neurochemistry in the pathophysiology of autism. *The Journal of clinical psychiatry*. 2005;66 Suppl 10:9-18.
5. Posey DJ, Erickson CA, McDougle CJ. Developing drugs for core social and communication impairment in autism. *Child Adolesc Psychiatr Clin N Am*. Oct 2008;17(4):787-801, viii-ix.
6. Goff DC, Tsai G, Levitt J, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. *Archives of general psychiatry*. Jan 1999;56(1):21-27.
7. van Berckel BN, Evenblij CN, van Loon BJ, et al. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. Aug 1999;21(2):203-210.
8. Goff DC, Cather C, Gottlieb JD, et al. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. *Schizophrenia research*. Dec 2008;106(2-3):320-327.
9. Goff DC, Herz L, Posey T, et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. *Psychopharmacology*. Apr 2005;179(1):144-150.
10. Duncan EJ, Szilagyi S, Schwartz MP, et al. Effects of D-cycloserine on negative symptoms in schizophrenia. *Schizophrenia research*. Dec 1 2004;71(2-3):239-248.
11. Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougle CJ. A pilot study of D-cycloserine in subjects with autistic disorder. *The American journal of psychiatry*. Nov 2004;161(11):2115-2117.
12. Posey DJ, Stigler, K.A., Erickson, C.A., Azzouz, F., Wilkerson, J., Mullett, J., McDougle, C.J. A double-blind, placebo-controlled study of D-cycloserine in children with autistic disorder. Paper presented at: American College of Neuropsychopharmacology 46th Annual Meeting December 9-13, 2007, 2007; Boca Raton, FL.
13. Swanson CJ, Bures M, Johnson MP, Linden A-M, Monn JA, Schoepp DD. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. *Nat Rev Drug Discov*. 02//print 2005;4(2):131-144.
14. Cortese BM, Phan KL. The role of glutamate in anxiety and related disorders. *CNS spectrums*. Oct 2005;10(10):820-830.
15. Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. *Biological psychiatry*. Jun 15 2008;63(12):1118-1126.
16. Rodrigues H, Figueira I, Lopes A, et al. Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis. *PLoS One*. 2014;9(7):e93519.
17. Modi ME, Young LJ. D-cycloserine facilitates socially reinforced learning in an animal model relevant to autism spectrum disorders. *Biological psychiatry*. Aug 1 2011;70(3):298-304.
18. Foxx RM. Applied behavior analysis treatment of Autism: The state of the art. *Child and Adolescent Psychiatric Clinics of North America*. 2008;17(4):821-834.
19. Lord C, Rutter M, Goode S, et al. Autism diagnostic observation schedule: a standardized observation of communicative and social behavior. *Journal of autism and developmental disorders*. Jun 1989;19(2):185-212.
20. Gotham K, Risi S, Pickles A, Lord C. The Autism Diagnostic Observation Schedule: revised algorithms for improved diagnostic validity. *Journal of autism and developmental disorders*. Apr 2007;37(4):613-627.
21. Lord C, Pickles A, McLennan J, et al. Diagnosing autism: analyses of data from the Autism Diagnostic Interview. *Journal of autism and developmental disorders*. Oct 1997;27(5):501-517.
22. Association AP. *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision*. Washington, DC: American Psychiatric Association; 2000.
23. Roid GH. *Stanford-Binet Intelligence Scales for Early Childhood, Fifth Edition*. 2005.
24. Sparrow SS, Cicchetti DV, Balla DA. *Vineland Adaptive Behavior Scales, Second Edition*. 2008.

25. Stone W, Ruble L, Coonrod E, Hepburn S, & Pennington M. *TRIAD Social Skills Assessment manual*. Nashville, TN: Treatment and Research Institute for Autism Spectrum Disorders; 2003.
26. Constantino JN, Gruber CP. *Social Responsiveness Scale*. 2005.
27. Sprafkin J, Gadow KD. *Child Symptom Inventory 4*. 2002.
28. Marrus N, Underwood-Riordan H, Randall F, Zhang Y, Constantino JN. Lack of effect of risperidone on core autistic symptoms: data from a longitudinal study. *Journal of child and adolescent psychopharmacology*. Nov 2014;24(9):513-518.
29. Lyall K, Constantino JN, Weisskopf MG, Roberts AL, Ascherio A, Santangelo SL. Parental social responsiveness and risk of autism spectrum disorder in offspring. *JAMA psychiatry*. Aug 2014;71(8):936-942.
30. Erickson CA, Veenstra-Vanderweele JM, Melmed RD, et al. STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study. *Journal of autism and developmental disorders*. Apr 2014;44(4):958-964.
31. Hardan AY, Fung LK, Libove RA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. *Biological psychiatry*. Jun 1 2012;71(11):956-961.
32. Aman MG, Singh NN. *Aberrant Behavior Checklist*. 1986.
33. Fisch GS. Adaptive behavior in children with autism. *Journal of autism and developmental disorders*. 2001;31(2):249-249.
34. Freeman BJ, Del'Homme M, Guthrie D, Zhang F. Vineland Adaptive Behavior Scale scores as a function of age and initial IQ in 210 autistic children. *Journal of autism and developmental disorders*. 1999;29(5):379-384.
35. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. *N Engl J Med*. Aug 1 2002;347(5):314-321.
36. Murray DS, Ruble LA, Willis H, Molloy CA. Parent and teacher report of social skills in children with autism spectrum disorders. *Language, Speech, and Hearing Services in Schools*. 2009;40(2):109-115.
37. Ruble L, Willis H, Crabtree VM. Social skills group therapy for autism spectrum disorders. *Clinical Case Studies*. 2008;7(4):287-300.
38. Association AP. *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition*. Washington, DC: American Psychiatric Association; 2013.
39. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. *Archives of general psychiatry*. Nov 2004;61(11):1136-1144.
40. Hofmann SG, Meuret AE, Smits JA, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. *Arch Gen Psychiatry*. Mar 2006;63(3):298-304.

Table 1. Sample Characteristics at Baseline

Characteristics	DCS (n=34)	Placebo (n=33)	p-value
Demographics			
Age (years), mean (SD)	8.38 (1.93)	8.25 (1.73)	.76
Sex, n (%) male	28 (82.35)	27 (81.82)	.95
Clinical Variables			
Stanford-Binet V, mean (SD)			
Full Scale IQ	92.42 (17.76)	87.30 (15.74)	.22
NonVerbal IQ	95.15 (18.03)	90.82 (15.19)	.30
Verbal IQ	90.85 (18.97)	85.45 (16.83)	.23
VABS-II Expressive Language subscale standard score, mean (SD)	87.38 (13.36)	84.55 (14.94)	.42
Clinical Global Impression-Severity	4.03 (0.18)	4.06 (0.24)	.58
Diagnosis, n (%)			
PDD-NOS	12 (35.29)	15 (45.45)	.40
Autistic Disorder	3 (8.82)	5 (15.15)	.48 ^a
Asperger's Disorder	19 (55.88)	13 (39.39)	.18
Concomitant medications, n (%)			
Antipsychotics	8 (23.53)	8 (24.24)	.95
Alpha-2 Agonists	6 (17.65)	8 (24.24)	.51
Stimulants	14 (41.18)	11 (33.33)	.51
Sleep Aids	9 (26.47)	7 (21.21)	.61
Mood Stabilizers	1 (2.94)	2 (6.06)	.61 ^a
Glutamatergic Modulators	1 (2.94)	0 (0.00)	1.00 ^a
Other	3 (8.82)	1 (3.03)	.61 ^a
Concomitant treatment, n (%)			
Speech Therapy	19 (55.88)	16 (51.52)	.72

Occupational Therapy	12 (35.29)	15 (45.45)	.40
Behavioral Therapy	9 (26.47)	9 (27.27)	.94
Other Psychotherapy	1 (2.94)	2 (6.06)	.61 ^a
Physical Therapy	0 (0.00)	2 (6.06)	.24 ^a
Social Skills Training	3 (8.82)	2 (6.06)	1.00 ^a
Music Therapy	0 (0.00)	1 (3.03)	.49 ^a
Other Treatments	3 (8.82)	0 (0.00)	.24 ^a

^a: Fisher's Exact Test

Table 2. Sample Characteristics at Enrollment Across Sites

Characteristics	Cincinnati (n=15)	Indiana University (n=52)	p-value
Demographics			
Age (years), mean (SD)	8.56 (1.77)	8.24 (1.84)	.56
Sex, n (%) male	11 (73.33)	44 (84.62)	.44 ^a
Group, n (%) Cycloserine	8 (53.33)	26 (50.00)	.82
Clinical Variables			
Stanford-Binet V, mean (SD)			
Full Scale IQ	87.86 (13.78)	90.40 (17.67)	.62
NonVerbal IQ	92.57 (15.36)	93.10 (17.17)	.92
Verbal IQ	85.29 (14.19)	88.92 (18.94)	.51
VABS-II Expressive Language subscale standard score, mean (SD)	84.67 (9.76)	86.37 (15.21)	.68
Clinical Global Impression-Severity	4.00 (0.00)	4.06 (0.24)	.38
Diagnosis, n (%)			
PDD-NOS	9 (60.00)	18 (34.62)	.08
Autistic Disorder	4 (26.67)	4 (7.69)	.07 ^a
Asperger's Disorder	2 (13.33)	30 (57.69)	.003 ^{a*}
Concomitant medications, n (%)			
Antipsychotics	2 (13.33)	14 (26.92)	.49 ^a
Alpha-2 Agonists	3 (20.00)	11 (21.15)	1.00 ^a
Stimulants	8 (53.33)	17 (32.69)	.15
Sleep Aids	3 (20.00)	13 (25.00)	1.00 ^a
Mood Stabilizers	0 (0.00)	3 (5.77)	1.00 ^a
Glutamatergic Modulators	0 (0.00)	1 (1.92)	1.00 ^a

Other	1 (6.67)	3 (5.77)	1.00 ^a
Concomitant treatment, n (%)			
Speech Therapy	6 (40.00)	30 (57.69)	.23
Occupational Therapy	6 (40.00)	21 (40.38)	.98
Behavioral Therapy	2 (13.33)	16 (30.77)	.32 ^a
Other Psychotherapy	0 (0.00)	3 (5.77)	1.00 ^a
Physical Therapy	1 (6.67)	1 (1.92)	.40 ^a
Social Skills Training	1 (6.67)	4 (7.69)	1.00 ^a
Music Therapy	1 (6.67)	0 (0.00)	.22 ^a
Other Treatments	1 (6.67)	2 (3.85)	.54 ^a

^a: Fisher's Exact Test

Table 3. Baseline, Week 11, and change in primary and secondary outcome measures

Clinical Outcome	DCS (n=34)			Placebo (n=33)			Difference in Change Scores (95% CI)	P-value
	Baseline	11-week	Change	Baseline	11-week	Change		
Primary outcome								
Social Responsiveness Scale (SRS) Parent Raw Scores								
Social awareness	12.82 (3.43)	12.15 (2.73)	-0.76 (2.60)	13.82 (3.59)	12.94 (2.67)	-1.00 (3.12)	0.24 (-1.19 to 1.67)	.74
Social cognition	19.18 (5.37)	17.21 (6.01)	-1.94 (4.41)	20.88 (4.34)	18.06 (4.24)	-2.68 (3.74)	0.74 (-1.31 to 2.79)	.47
Social communication	34.94 (8.65)	30.00 (8.55)	-4.91 (6.49)	37.97 (7.84)	32.03 (7.71)	-6.19 (8.40)	1.28 (-2.45 to 5.02)	.49
Social motivation	16.06 (5.84)	13.18 (5.01)	-2.76 (3.95)	16.33 (5.34)	13.39 (5.17)	-3.06 (4.40)	0.31 (-1.78 to 2.40)	.54
Autistic mannerisms	19.44 (6.10)	16.42 (6.03)	-2.82 (5.24)	21.42 (6.27)	17.65 (5.36)	-4.10 (6.38)	1.28 (-1.63 to 4.19)	.38
SRS Parent Total Score	102.35 (25.09)	88.67 (22.74)	-13.39 (16.81)	110.33 (20.43)	94.00 (19.31)	-17.00 (21.33)	3.61 (-5.96 to 13.17)	.45
Secondary outcomes								
VABS-II raw scores								
Communication	152.56 (17.05)	156.47 (17.85)	3.63 (8.26)	147.06 (22.18)	154.58 (21.93)	6.77 (11.15)	-3.15 (-8.08 to 1.79)	.21
Daily living skills	231.62 (26.08)	239.56 (26.99)	7.06 (14.72)	229.67 (35.43)	239.29 (35.76)	8.45 (16.82)	-1.39 (-9.35 to 6.57)	.73

Socialization	113.26 (24.98)	126.53 (27.54)	12.34 (20.00)	103.97 (22.14)	117.35 (27.94)	12.10 (22.28)	0.25 (-10.41 to 10.91)	.96
Motor skills	141.21 (7.21)	143.59 (5.42)	2.22 (5.70)	141.27 (9.50)	142.19 (9.59)	0.19 (3.81)	2.03 (-0.41 to 4.46)	.10
Maladaptive behavior	16.65 (6.87)	15.88 (7.12)	-0.59 (5.92)	18.55 (7.42)	16.42 (5.59)	-2.03 (5.91)	1.44 (-1.54 to 4.42)	.34
Total	655.29 (59.88)	682.03 (64.28)	24.66 (37.56)	640.52 (78.65)	669.84 (83.74)	25.48 (41.11)	-0.83 (-20.66 to 19.00)	.93
ABC parent score								
Irritability	11.06 (8.05)	9.12 (6.63)	-1.55 (6.11)	12.67 (8.96)	11.06 (7.42)	-1.23 (6.09)	-0.32 (-3.37 to 2.73)	.83
Social Withdrawal	10.29 (8.30)	8.06 (7.61)	-2.39 (4.71)	10.39 (8.33)	8.81 (6.41)	-1.71 (7.04)	-0.68 (-3.71 to 2.34)	.65
Stereotypy	4.94 (4.21)	4.64 (4.89)	-0.33 (2.79)	4.64 (4.32)	4.32 (3.75)	-0.45 (4.60)	0.12 (-1.81 to 2.04)	.90
Hyperactivity	18.82 (11.26)	17.30 (12.23)	-1.55 (7.37)	19.00 (9.18)	16.87 (9.49)	-2.03 (9.39)	0.49 (-3.72 to 4.69)	.82
Inappropriate speech	3.91 (3.04)	3.24 (2.26)	-0.73 (2.59)	4.36 (2.85)	4.68 (3.29)	0.35 (2.67)	-1.08 (-2.40 to 0.23)	.10
TSSA parent	53.74 (8.61)	57.84 (9.11)	3.88 (3.49)	48.79 (8.91)	54.34 (10.37)	5.83 (9.70)	-1.95 (-6.87 to 2.97)	.43

Table 4 Adverse Events by Treatment Group

	Number (%) of patients reporting		
Adverse Event	DCS (N=34)	Placebo (N=33)	p value
Any Adverse Event	32 (94.1)	28 (84.8)	0.26
Headache (including sinus headache)	9 (26.5)	7 (21.2)	0.80
Nasal congestion or Cold	6 (17.6)	8 (24.2)	0.79
Cough	7 (20.6)	7 (21.2)	0.99
Vomiting	6 (17.6)	2 (6.1)	0.29
Aggression	2 (5.9)	5 (15.2)	0.45
Increased motor activity	1 (2.9)	5 (15.2)	0.22
Interrupted sleep/ other sleep problems	3 (8.8)	5 (15.2)	0.73
Irritability (including agitation)	16 (47.1)	15 (45.5)	0.99
Restlessness/Agitation	4 (11.8)	3 (9.1)	0.99
Sadness	5 (14.7)	3 (9.1)	0.73
Sedation/Drowsiness	2 (5.9)	6 (18.2)	0.29
Not otherwise listed	10 (29.4)	12 (36.4)	0.83
Any Serious Adverse Event	0	1 (3.0)	0.99

Figure 1. Social Responsiveness Scale Raw Score Across Time Points

